Cullinan Therapeutics Inc News - CGEM

SVB Securities Thinks Cullinan Management’s Stock is Going to Recover

In a report released today, Andrew Berens from SVB Securities maintained a Buy rating on Cullinan Management (CGEM – Research Report), with a...

Current Report Filing (8-k)

false 0001789972 0001789972 2022-05-11 2022-05-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl

Taiho obtains exclusive global rights to CLN-081/TAS6417 outside the U.S.; in the U.S., Taiho and Cullinan...

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today...

Additional Proxy Soliciting Materials (definitive) (defa14a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Proxy Statement (definitive) (def 14a)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting

CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan), a...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences

CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a...

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”...

H.C. Wainwright Keeps Their Buy Rating on Cullinan Management (CGEM)

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Cullinan Management (CGEM – Research Report), with a...

Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients

Confirmed overall response rate improves to 41% at 100mg BID dose level Continued favorable safety and...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Cullinan Therapeutics Inc (CGEM)

Empower your portfolio: Real-time discussions and actionable trading ideas.

CGEM News

SVB Securities Thinks Cullinan Management’s Stock is Going to Recover

Current Report Filing (8-k)

Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Additional Proxy Soliciting Materials (definitive) (defa14a)

Proxy Statement (definitive) (def 14a)

Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting

Statement of Changes in Beneficial Ownership (4)

Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

H.C. Wainwright Keeps Their Buy Rating on Cullinan Management (CGEM)

Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

CGEM Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Cullinan Therapeutics Inc (CGEM) News

Cullinan Therapeutics Inc (CGEM)

Empower your portfolio: Real-time discussions and actionable trading ideas.

CGEM News

SVB Securities Thinks Cullinan Management’s Stock is Going to Recover

Current Report Filing (8-k)

Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Additional Proxy Soliciting Materials (definitive) (defa14a)

Proxy Statement (definitive) (def 14a)

Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting

Statement of Changes in Beneficial Ownership (4)

Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

H.C. Wainwright Keeps Their Buy Rating on Cullinan Management (CGEM)

Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

CGEM Discussion

Your Recent History